Live Analyst Rating Changes 27546 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Martin PhD
BB

David Martin PhD

Bloom Burton
Wall Street Analyst
★★★★☆
#449
on 13Foresight · ranked by our own returns
47%
Success Rate
+14.7%
Average Return
14 of 30 calls profitable · +63.2% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 47% of David Martin PhD's ratings turned a profit when each position was held for 2 year — averaging +14.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

56 Buy 5 Hold 0 Sell
David's Stock Coverage 18 ratings · 2026-08-26
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return vs S&P 500 ⓘ
TSE:RX
Biosyent
 Aug 24, 2026 BUY Strong Buy
+14.7% avg upside
1 analyst
$18.00
14.71% Upside
 · ·
AUPH
Aurinia Pharmaceuticals
 Aug 20, 2026 BUY Strong Buy
-4.8% avg upside
12 analysts
$21.00
25.46% Upside
 -3.5% ·
TSE:MBX
Microbix Biosystms
 Aug 14, 2026 BUY Strong Buy
+33.3% avg upside
1 analyst
$0.40
33.34% Upside
 +0.0% ·
TSE:APTX
Apotex Health Corp.
 Aug 13, 2026 BUY Strong Buy
+20.7% avg upside
10 analysts
$40.00
19.14% Upside
 -4.7% ·
TSE:HLS
HLS Therapeutics Inc
 Aug 13, 2026 BUY Strong Buy
+135.3% avg upside
4 analysts
$12.00
212.56% Upside
 -3.1% ·
TSE:MDP
Medexus Pharmaceuticals Inc
 Aug 12, 2026 BUY Strong Buy
+8.2% avg upside
5 analysts
$6.50
26.16% Upside
 -4.3% ·
TSE:GUD
Knight Therapeutics
 Aug 07, 2026 BUY Strong Buy
-6.3% avg upside
7 analysts
$12.00
23.17% Upside
 -1.0% ·
AU:PYC
PYC Therapeutics Limited
 Aug 05, 2026 BUY Strong Buy
+61.0% avg upside
3 analysts
$5.00
134.13% Upside
 -2.8% ·
TSE:EPRX
Eupraxia Pharmaceuticals
 Aug 03, 2026 BUY Strong Buy
+118.8% avg upside
9 analysts
$19.39
90.20% Upside
 +2.0% ·
TSE:CRRX
CareRx
 Jul 31, 2026 BUY Strong Buy
+67.2% avg upside
5 analysts
$5.00
54.41% Upside
 -12.4% ·
HELP
Helus Pharma
 Jul 21, 2026 BUY Strong Buy
+169.6% avg upside
13 analysts
$47.00
236.15% Upside
 +55.4% ·
ZYME
Zymeworks
 Jun 29, 2026 BUY Strong Buy
+21.0% avg upside
25 analysts
$36.00
31.11% Upside
 +19.0% ·
XENE
Xenon
 Mar 09, 2026 BUY Strong Buy
+2.9% avg upside
28 analysts
$74.00
22.52% Upside
 -3.7% ·
TSE:MDNA
Medicenna Therapeutics Corp
 Dec 11, 2025 BUY Strong Buy
+970.4% avg upside
9 analysts
$4.00
751.01% Upside
 -65.2% ·
ABCL
AbCellera Biologics
 Nov 19, 2025 BUY Strong Buy
+32.6% avg upside
15 analysts
$9.00
28.09% Downside
 +232.8% ·
VRDN
Viridian Therapeutics
 Oct 21, 2025 BUY Strong Buy
+45.4% avg upside
32 analysts
$14.22
41.20% Downside
 +0.0% ·
TSE:DHT.UN
DRI Healthcare
 Jul 18, 2025 BUY Strong Buy
+13.8% avg upside
6 analysts
$19.00
6.80% Upside
 +31.9% ·
TSE:CNVI
Conavi Medical
 Jul 06, 2025 BUY Buy
+890.9% avg upside
4 analysts
$1.00
524.97% Upside
 · ·
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Martin PhD — Frequently Asked Questions
How accurate are David Martin PhD's stock ratings?
Based on the calls 13Foresight could measure, about 45% of David's ratings were profitable over a one-year hold, with an average return of +12.8% per rating, or +62.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is David ranked on 13Foresight?
David Martin PhD is currently ranked #449 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on TSE:RX, AUPH, TSE:MBX, TSE:APTX, TSE:HLS, TSE:MDP, TSE:GUD, AU:PYC, TSE:EPRX, TSE:CRRX, HELP, ZYME and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.